Anti-KEAP1 antibody (320-510) (STJ24306)
SPECIFICATIONS
ClonalityPolyclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG
General Information
| Short Description | Rabbit polyclonal KEAP1 (320-510) antibody for use in WB, IHC-P, IF, ICC and ELISA in human, mouse and rat samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | WB/IHC-P/IF/ICC/ELISA |
| Host | Rabbit |
| Reactivity | Human/Mouse/Rat |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Concentration | Lot specific |
| Purification | Affinity purification |
| Dilution Range | WB:1:100-1:500IHC-P:1:50-1:200IF/ICC:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Formulation | PBS with 0.09% Sodium Azide, 50% Glycerol, pH7.3. |
| Storage Instruction | Store at-20ยฐC for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Target Information
| Gene Symbol | KEAP1 |
| Gene ID | 9817 |
| Uniprot ID | KEAP1_HUMAN |
| Immunogen Region | 320-510 |
| Immunogen Sequence | RAPKVGRLIYTAGGYFRQSL SYLEAYNPSDGTWLRLADLQ VPRSGLAGCVVGGLLYAVGG RNNSPDGNTDSSALDCYNPM TNQWSPCAPMSVPRNRIGVG VIDGHIYAVGGSHGCIHHNS VERYEPERDEWHLVAPMLTR RIGVGVAVLNRLLYAVGGFD GTNRLNSAECYYPERNEWRM ITAMNTIRSGA |
| Specificity | Recombinant fusion protein containing a sequence corresponding to amino acids 320-510 of human KEAP1 (NP_036421.2). |
Additional Info
| Tissue Specificity | Broadly expressed, with highest levels in skeletal muscle. |
| Post Translational Modifications | Non-enzymatic covalent modifications of reactive cysteines by electrophile metabolites inactivate the BCR(KEAP1) complex. Accumulation of fumarate promotes the formation of cysteine S-succination (S-(2-succinyl)cysteine), leading to inactivate the BCR(KEAP1) complex and promote NFE2L2/NRF2 nuclear accumulation and activation. Nitric oxide-dependent 8-Nitro-cGMP formation promotes cysteine guanylation (S-cGMP-cysteine), leading to NFE2L2/NRF2 nuclear accumulation and activation. Itaconate, an anti-inflammatory metabolite generated in response to lipopolysaccharide, alkylates cysteines, activating NFE2L2/NRF2. Methylglyoxal, a reactive metabolite that accumulates when the glycolytic enzyme PGK1 is inhibited, promotes formation of a methylimidazole cross-link between proximal Cys-151 and Arg-135 on another KEAP1 molecule, resulting in an inactive dimer that inactivates the BCR(KEAP1) complex. Degraded via a proteasomal-independent process during selective autophagy: interaction with phosphorylated SQSTM1/p62 sequesters KEAP1 in inclusion bodies, leading to its degradation. Auto-ubiquitinated by the BCR(KEAP1) complex. Quinone-induced oxidative stress, but not sulforaphane, increases its ubiquitination. Ubiquitination and subsequent degradation is most pronounced following prolonged exposure of cells to oxidative stress, particularly in glutathione-deficient cells that are highly susceptible to oxidative stress. Deubiquitinated by USP25.leading to stabilization. Ubiquitinated by TRIM25.leading to degradation upon ER stress. |
| Function | Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination. KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes. In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes. In response to selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2. The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation. The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome. |
| Protein Name | Kelch-Like Ech-Associated Protein 1Cytosolic Inhibitor Of Nrf2Inrf2Kelch-Like Protein 19 |
| Database Links | Reactome: R-HSA-5689880Reactome: R-HSA-8951664Reactome: R-HSA-9679191Reactome: R-HSA-9755511Reactome: R-HSA-9759194Reactome: R-HSA-983168 |
| Cellular Localisation | CytoplasmNucleusMainly CytoplasmicIn Response To Selective AutophagyRelocalizes To Inclusion Bodies Following Interaction With Sqstm1/P62 |
| Alternative Antibody Names | Anti-Kelch-Like Ech-Associated Protein 1 antibodyAnti-Cytosolic Inhibitor Of Nrf2 antibodyAnti-Inrf2 antibodyAnti-Kelch-Like Protein 19 antibodyAnti-KEAP1 antibodyAnti-INRF2 antibodyAnti-KIAA0132 antibodyAnti-KLHL19 antibody |
Information sourced from Uniprot.org